Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Aug 06, 2019

SELL
$7.67 - $10.63 $30,680 - $42,520
-4,000 Closed
0 $0
Q1 2019

May 10, 2019

SELL
$7.58 - $9.94 $6,064 - $7,952
-800 Reduced 16.67%
4,000 $40,000
Q4 2018

Feb 12, 2019

BUY
$7.16 - $16.21 $18,616 - $42,146
2,600 Added 118.18%
4,800 $37,000
Q3 2018

Nov 14, 2018

BUY
$9.7 - $19.65 $21,340 - $43,230
2,200 New
2,200 $34,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.83B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Cable Hill Partners, LLC Portfolio

Follow Cable Hill Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cable Hill Partners, LLC with notifications on news.